A5037359603- Adenosine and Purinergic Signaling
- Synthesis and Biological Evaluation
- Pneumocystis jirovecii pneumonia detection and treatment
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
Abstract T cells play a critical role in the control of cancer. The development immune checkpoint blockers (ICB) aimed at enhancing antitumor T-cell responses has revolutionized cancer treatment. However, durable clinical benefit is observed only subset patients, prompting research efforts to focus on strategies that target multiple inhibitory signals within tumor microenvironment (TME) limit evasion and improve patient outcomes. Adenosine emerged as potent suppressant TME, CD73 major enzyme...
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Data from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Data from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
<div>Abstract<p>T cells play a critical role in the control of cancer. The development immune checkpoint blockers (ICB) aimed at enhancing antitumor T-cell responses has revolutionized cancer treatment. However, durable clinical benefit is observed only subset patients, prompting research efforts to focus on strategies that target multiple inhibitory signals within tumor microenvironment (TME) limit evasion and improve patient outcomes. Adenosine emerged as potent suppressant...
<div>Abstract<p>T cells play a critical role in the control of cancer. The development immune checkpoint blockers (ICB) aimed at enhancing antitumor T-cell responses has revolutionized cancer treatment. However, durable clinical benefit is observed only subset patients, prompting research efforts to focus on strategies that target multiple inhibitory signals within tumor microenvironment (TME) limit evasion and improve patient outcomes. Adenosine emerged as potent suppressant...